{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000003","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.238837+00:00","generated_at":"2026-05-26T01:10:53.759353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86","bullets":["Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).","FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).","Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).","Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.","CEO cites progress on proprietary pipeline for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000003","json":"https://secwatch.observer/filing/0001297184-25-000003.json","markdown":"https://secwatch.observer/filing/0001297184-25-000003.md","text":"https://secwatch.observer/filing/0001297184-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/0001297184-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/amph-20250227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:10:53.759353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}